| NCT03949283 | III | Platinum resistant ovarian cancer | Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | CA, FL, LA, OH, OK, PA, WV | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05092360 | III | Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab (5 or less prior therapies for platinum resistant disease) | A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7) | AL, AK, AZ, CA, FL, IL, IN, KY, LA, MD, MI, NJ, NM, NY, NC, OH, OR, PA, SD, TX, VA | View Drugs | View Results |
Nemvaleukin alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2R/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05257408 | III | Platinum resistant high grade serous or high grade endometrioid ovarian cancer that must have had prior bevacizumab | A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA) | AZ, CA, CO, FL, GA, IL, IN, KS, KY, NJ, NM, NY, OH, OR, PA, SD, TN, TX, VA, WI | View Drugs | View Results |
nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Relacorilant | RELA, CORT125134 | GR antagonist | Clinical Trials |
|
|
| NCT05281471 | III | Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab - intraperitoneal infusion | A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076) | AL, AZ, CA, FL, IN, MD, MI, MO, NC, OH, OK | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Olvimulogene nanivacirepvec | light-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1 | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT02693535 | II | Ovarian expansion for CDKN2A loss or mutation or ERBB2/ERBB3 amplification, mutation or over-expression, or high TMB or Advanced solid tumors with molecular alterations in AKT1, ATM, ATR, BRAF, BRCA1/2, CDK4/6 AMP, CDK12, CDKN2A, CDKN2B, CHEK2, CSF1R, FANCA, FGFR1/2/3/4, FLT3, KIT, MRE11A, MLH1, MSH2, MSH6, NBN, NTRK1/2/3 AMP, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RAD51C, RET, TSC1/2, VEGFR, or with high MSI, high TMB, HRD+, or LOHhi | Targeted Agent and Profiling Utilization Registry (TAPUR) Study | AL, AZ, CA, CT, FL, GA, IL, IN, ME, MI, NE, NH, NM, NY, NC, ND, OH, OR, PA, SC, SD, TN, TX, UT, VA, WA, WI | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Futibatinib | TAS-120, FGFR inhibitor TAS-120 | FGFR1-4 inhibitor | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Larotrectinib | Trk inhibitor LOXO-101, LOXO-101, Vitrakvi | pan-Trk kinase inhibitor | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | Approved in Other Cancers | PHESGO | pertuzumab, trastuzumab, and hyaluronidase-zzxf | HER2 antagonist | Approved in Other Cancers | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | Approved in Other Cancers | Sunitinib | Sutent, Sunitinib malate | VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | Temsirolimus | Torisel, CCI-779 | mTOR inhibitor | Approved in Other Cancers | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Approved in Other Cancers | Tucatinib | Irbinitinib, ONT-380 | HER2 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT02628067 | II | Advanced solid tumors with high MSI or high TMB | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) | CA, MA, NJ | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02675829 | II | Advanced solid tumors with HER2 amplification | A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | NJ, NY | View Drugs | View Results |
Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers |
|
|
| NCT03026062 | II | Platinum resistant or refractory clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell component | Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer | TX | View Drugs | View Results |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tremelimumab | Ticilimumab, CP-675206, CP-675,206, CP-675, anti-CTLA4 human monoclonal antibody CP-675,206 | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03212274 | II | Advanced solid tumors with IDH1 or IDH2 mutations | A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors | CA, FL, KS, MD, MA, MO, NH, NC, OH, OK, PA, TN, TX, UT, WI | View Drugs | |
|
|
| NCT03310879 | II | Advanced solid tumors with CCND1/2/3 alterations or CDK4/6 amplifications | A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 | MA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT03412877 | II | Advanced solid tumors | A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer | MD | View Drugs | View Results |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Individual Patient TCR-Transduced PBL | autologous PBLs retrovirally-transduced with TCRs targeting neoantigens | Immune response against neoantigens | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03428802 | II | Advanced solid tumors with high MSI and with POLE, POLD, or BRCA1/2 mutations | A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability | NJ, NY | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03682289 | II | Advanced solid tumors with ARID1A or ATM alterations | Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies | CA | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03693014 | II | Advanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatment | A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade | CT, NJ, NY, PA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT03574779 | II | Platinum resistant ovarian cancer or Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) | A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL) | CA, IL, ME, MA, MN, OK, SD, WA | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Dostarlimab | TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Niraparib | MK4827, Zejula | PARP inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03732950 | II | Recurrent ovarian cancer | A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling | CA, MN | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03742895 | II | Advanced solid tumors without BRCA1/2 mutations, with Homologous Recombination Repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+ | A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer | MD, NJ, NY, WA | View Drugs | View Results |
|
|
| NCT03878849 | II | Recurrent ovarian cancer | Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® | OK, WA | View Drugs | View Results |
Stenoparib | PARP/Tankyrase inhibitor 2X-121, E7449, 2X-121 | PARP inhibitor | Clinical Trials |
|
|
| NCT01174121 | II | Advanced solid tumors | A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab | MD | View Drugs | View Results |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Selected Young TIL | | Immune response against tumor-associated antigens | Clinical Trials |
|
|
| NCT03907475 | II | Advanced solid tumors (with tumor amenable to skin biopsy) | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors | MD | View Drugs | View Results |
Capecitabine | CAPE, Xeloda | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03935893 | II | Advanced solid tumors | A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers | PA | View Drugs | View Results |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Autologous TILs | | Immune response against tumor-associated antigens | Clinical Trials | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers |
|
|
| NCT02710253 | II | Advanced solid tumors that must have progressed on prior immunotherapy or cellular therapy (amenable to radiation therapy) | Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy | TX | View Drugs | View Results |
Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT03994796 | II | Advanced solid tumors with brain metastases and NTRK, ROS1, KRAS G12C, CDK pathway or PI3K pathway alterations | Genomically-Guided Treatment Trial in Brain Metastases | AK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Adagrasib | KRAS G12C inhibitor MRTX849, MRTX849 | KRAS G12C inhibitor | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Paxalisib | GDC-0084, PI3K inhibitor GDC-0084, RG7666 | PI3K/mTOR inhibitor | Clinical Trials |
|
|
| NCT04055649 | II | Platinum resistant or refractory ovarian cancer (at most 4 prior therapies for platinum resistant disease) | Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | MI | View Drugs | View Results |
ONC201 | AKT/ERK inhibitor ONC201, TIC10 | AKT and ERK kinase inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04198766 | II | Advanced solid tumors with dMMR, high MSI or high TMB | An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors | CA, GA, IL, IA, KY, MI, NE, OR, TN, TX, VA, WI | View Drugs | View Results |
INBRX-106 | INBRX-106: Hexavalent OX40 Agonist | Stimulates OX40 to increase T cell activation and immune response | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04449549 | II | Recurrent rare tumors | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | MD | View Drugs | View Results |
Nilotinib | AMN 107, Tasigna | Bcr-abl, c-Kit, and PDGFR kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04469764 | II | Recurrent ovarian cancer with CCND1-3 or CDK4/6 amplifications or CDKN2A alterations | An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer | CA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Anastrozole | Arimidex | Aromatase inhibitor | | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT04534283 | II | Advanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1 | A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1. | IN | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Temuterkib | LY3214996 | ERK inhibitor | Clinical Trials |
|
|
| NCT04592653 | II | Recurrent ovarian cancer | Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3 | MI, TX, UT, VA | View Drugs | View Results |
Nemvaleukin alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2R/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04589845 | II | Advanced solid tumors with alterations in ALK, ATM, BRAF (class III), KRAS G12C, NTRK1/2/3, PIK3CA (multiple mutations), RET, ROS1 or SETD2 | Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial | AL, AZ, CA, CO, FL, GA, ID, MD, MI, MN, MT, NH, NJ, NM, NY, OH, PA, TN, TX, VA, WA, WI | View Drugs | View Results |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers | Belvarafenib | HM95573 | BRAF kinase inhibitor | Clinical Trials | Camonsertib | RP-3500 | ATR kinase inhibitor | Clinical Trials | Divarasib | GDC-6036 | KRAS G12C inhibitor | Clinical Trials | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Inavolisib | RG6114, GDC-0077 | PI3K alpha inhibitor | Clinical Trials | Pralsetinib | BLU-667 | RET-kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04625270 | II | Recurrent low grade serous ovarian cancer | A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | AZ, CA, CT, FL, IL, MD, MN, MO, NV, NM, NY, OH, OK, OR, TN, TX, VA | View Drugs | View Results |
Avutometinib | CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766 | RAF and MEK inhibitor | Clinical Trials | Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials |
|
|
| NCT04739618 | II | Advanced solid tumors - intratumoral injection | A Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid Cancer | AZ | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Thermotherapy | | | Clinical Trials |
|
|
| NCT04771520 | II | Advanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I) | Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors | TX | View Drugs | |
Avapritinib | | PDGFRa and c-Kit inhibitor | Approved in Other Cancers |
|
|
| NCT04781088 | II | Platinum resistant ovarian cancer | Phase II Study With Safety Lead-In of Lenvatinib, Pembrolizumab, and Weekly Paclitaxel for Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer | OH, PA | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02896335 | II | Patients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A | A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway | MA | View Drugs | View Results |
Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT04102436 | II | Advanced solid tumors | A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer | MD | View Drugs | |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Sleeping Beauty Transposed PBL | | Immune response against neoantigens | Clinical Trials |
|
|
| NCT04876456 | II | Recurrent Germ Cell Tumors | A Phase II Trial Evaluating the Efficacy of Cabozantinib in the Treatment of Incurable Patients With Refractory Germ Cell Tumors | IN | View Drugs | |
Cabozantinib | BMS-907351, Cabometyx, XL184, Cometriq | Multi-targeted RTK inhibitor | Approved in Other Cancers |
|
|
| NCT04879121 | II | Advanced solid tumors with NTRK1-3 amplifications (at least 7 copies) | A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive Tumors | TX | View Drugs | View Results |
Larotrectinib | Trk inhibitor LOXO-101, LOXO-101, Vitrakvi | pan-Trk kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04918186 | II | Platinum resistant high grade serous ovarian cancer (at most 1 prior therapy for platinum resistant disease) | An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | IL | View Drugs | |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Mecbotamab Vedotin | CAB-AXL-ADC, BA3011, conditionally active biologic anti-AXL antibody-drug conjugate BA3011 | ADC: anti-Axl + microtubule destabilizer (MMAE) | Clinical Trials | Ozuriftamab Vedotin | BA3021 | ADC: anti-ROR2 + microtubule destabilizer (MMAE) | Clinical Trials |
|
|
| NCT04919629 | II | Recurrent ovarian cancer with symptomatic ascites or pleural effusion | Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion | NY | View Drugs | |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Pegcetacoplan | C3-targeted complement inhibitor APL-2, APL-2 | Blocks the cleavage of C3 | Approved in Other Indications | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04931342 | II | Platinum resistant low-grade serous, low-grade endometrioid, clear cell, mucinous, undifferentiated, malignant Brenner tumors, small cell carcinoma of the ovary-hypercalcemic type or carcinosarcoma | A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | AZ, CA, MN, NC, OH, OK, OR, PA, TX, UT, VA, WA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Cobimetinib | XL518, GDC-0973, Cotellic | MEK1 inhibitor | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Giredestrant | GDC-9545, selective estrogen receptor downregulator GDC-9545 | ER antagonist (SERD) | Clinical Trials | Inavolisib | RG6114, GDC-0077 | PI3K alpha inhibitor | Clinical Trials | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers |
|
|
| NCT04957615 | II | Advanced solid tumors with ARID1A mutations | A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid Tumors | TX | View Drugs | |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04983745 | II | Advanced solid tumors with somatic mutations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCI/L, PALB2, PPP2R2A, RAD51B/C/D or RAD54L | A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer | TN | View Drugs | View Results |
Dostarlimab | TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Niraparib | MK4827, Zejula | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05023655 | II | Advanced solid tumors with ARID1A mutations | A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | SC | View Drugs | View Results |
Tazemetostat | histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438, Tazverik | EZH2 histone methyltransferase inhibitor | Approved in Other Cancers |
|
|
| NCT05032040 | II | Platinum resistant high grade serous or recurrent clear cell ovarian cancer (at most 2 prior chemotherapy regimens) | A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer | CA, FL, GA, MI, NV, NY, PA | View Drugs | View Results |
Vudalimab | XmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717 | Blocks PD-1 and CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT05064280 | II | Advanced solid tumors with brain metastases | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | TX | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05071937 | II | Recurrent ovarian cancer with prior PARP inhibitor (at most 4 prior chemotherapy regimens) | Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer | PA | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | ZEN-3694 | ZEN003694, BET bromodomain inhibitor ZEN-3694 | BET inhibitor | Clinical Trials |
|
|
| NCT05082025 | II | Recurrent ER+ and/or PR+ ovarian cancer with alterations in PIK3CA, PIK3R1 or PTEN | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | TX | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Fulvestrant | ZD9238, ICI 182,780, Faslodex | ER antagonist (SERD) | Approved in Other Cancers |
|
|
| NCT05097599 | II | Advanced solid tumors with ALK or ROS1 fusions, BRAF V600X, BRCA1/2, or gPALB2 alterations, or HER2+, Nectin-4+ or TROP2+, or IRS-H+ or Angio TRS-H+ | Strata PATHâ„¢ (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid Tumors | DE, FL, OH, TN, WI | View Drugs | View Results |
Axitinib | Inlyta, AG-013736 | Multi-targeted RTK inhibitor | | Binimetinib | MEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, Mektovi | MEK inhibitor | Approved in Other Cancers | Encorafenib | Raf Kinase Inhibitor LGX818, LGX818 | RAF inhibitor | Approved in Other Cancers | Enfortumab Vedotin | | ADC: anti-Nectin-4 + microtubule destabilizer (MMAE) | Approved in Other Cancers | Lorlatinib | PF-06463922 | ALK and ROS1 kinase inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Sacituzumab govitecan | Trodelvy, hrS7-SN38 antibody drug conjugate, anti-TROP-2 Antibody-Drug Conjugate IMMU-132 | ADC: anti-TROP2 + topoisomerase I inhibitor (SN38) | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | Trastuzumab deruxtecan | T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a | ADC: anti-HER2 + topoisomerase I inhibitor (Dxd) | Approved in Other Cancers |
|
|
| NCT05103358 | II | Advanced solid tumors with TSC1/2 alterations | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | AL, AZ, CA, CO, CT, FL, GA, HI, IN, LA, MD, MA, MI, MO, NE, NV, NJ, NY, NC, OH, OK, PA, SC, SD, TN, TX, UT, VA, WA, WI | View Drugs | View Results |
nab-Sirolimus | Nanoparticle Albumin-Bound Sirolimus, Nanoparticle Albumin-Bound Rapamycin, nab-rapamycin, ABI-009 | mTOR inhibitor | Approved in Other Cancers |
|
|
| NCT05113368 | II | Recurrect low grade serous ovarian cancer | Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial | OH | View Drugs | |
Fulvestrant | ZD9238, ICI 182,780, Faslodex | ER antagonist (SERD) | Approved in Other Cancers | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | Approved in Other Cancers |
|
|
| NCT05114421 | II | Platinum resistant or refractory high grade serous ovarian cancer with disease present in the peritoneal cavity or retroperitoneal lymph nodes | Immunomodulation of the Tumor Microenvironment in High-Grade Serous Ovarian Cancer Patients Receiving Pembrolizumab and Lenvatinib Monotherapy and Combination Therapy | TX | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05128825 | II | Platinum resistant high grade serous ovarian cancer that must have had prior bevacizumab | A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI) | AL, AZ, FL, GA, IL, IN, MA, MO, NV, NY, NC, OH, PA, SD, TX | View Drugs | View Results |
Azenosertib | ZN-c3 | WEE1 inhibitor | Clinical Trials |
|
|
| NCT05185947 | II | Recurrent or persistent non-mucinous ovarian cancer with peritoneal disease (IP/IV) | Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | MD | View Drugs | View Results |
Nilotinib | AMN 107, Tasigna | Bcr-abl, c-Kit, and PDGFR kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05199584 | II | Advanced solid tumors with loss of function PTCH1 mutations | A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | CA, FL, IL, LA, NV, NY, NC, OH, PA, TN, TX, VA, WI | View Drugs | |
Taladegib | LY2940680, ENV-101 | Smoothened antagonist | Clinical Trials |
|
|
| NCT04992013 | II | Ovarian cancer with brain metastases and alterations in ATM, ATR, BAP1, BARD1, BRCA1/2, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, RAD54B/L, XRCC2, or XRCC3 (with measurable disease in the CNS) | Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS | MA | View Drugs | View Results |
|
|
| NCT05231122 | II | Recurrent serous, endometrioid or clear cell ovarian cancer | Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer | NY, TX | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | CDX-1140 | | Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05262400 | II | Advanced solid tumors | A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | CA, MA, MI, MO, TX, WA | View Drugs | View Results |
PF-07104091 | | CDK2 inhibitor | Clinical Trials | PF-07220060 | | CDK4 inhibitor | Clinical Trials |
|
|
| NCT05272462 | II | Platinum resistant ovarian cancer | A Phase II Trial of Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer | IL | View Drugs | |
Minoxidil | | Kir6/SUR2 channel activator | Approved in Other Indications |
|
|
| NCT05286801 | II | Advanced solid tumors with loss of SMARCB1 or SMARCA1 | A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | AL, CA, CO, DC, IL, IN, MD, MA, MI, MN, MO, NY, NC, OH, PA, TN, TX, UT | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tiragolumab | MTIG7192A, RO7092284 | Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cells | Clinical Trials |
|
|
| NCT05296512 | II | Recurrent or persistent clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell component | A Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary | MA, MN | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05327010 | II | Advanced solid tumors with alterations in BARD1, BRCA 1/2, BRIP1, FANCA, PALB2; RAD51 or RAD51C/D with PARP inhibitor therapy as immediate prior therapy or advanced solid tumors with a KRAS G12C mutation with prior KRAS G12C targeted therapy or platinum sensitive ovarian cancer without BRCA1/2 mutations with CR/PR on prior PARP inhibitor | Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET) | CA, CO, GA, IL, NC, PA, TX, VA | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | ZEN-3694 | ZEN003694, BET bromodomain inhibitor ZEN-3694 | BET inhibitor | Clinical Trials |
|
|
| NCT05337735 | II | Advanced solid tumors with dMMR or high MSI | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | TX | View Drugs | View Results |
Vudalimab | XmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717 | Blocks PD-1 and CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT05446298 | II | Platinum resistant high grade serous ovarian cancer; must have received prior bevacizumab | Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC) | AZ, CT, FL, IL, IN, KY, LA, MN, NV, NJ, NY, OH, OR, TX, WI | View Drugs | View Results |
Gotistobart | ONC-392 | Blocks CTLA-4 inhibition of T cells | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05453825 | II | Platinum resistant or refractory ovarian cancer | A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors | AR, CA, FL, GA, LA, NY, OH, TN | View Drugs | View Results |
Navicixizumab | OMP-305B83, anti-DLL4/VEGF bispecific monoclonal antibody OMP-305B83 | DLL4 and VEGF antagonist | Clinical Trials |
|
|
| NCT05467670 | II | Platinum resistant ovarian cancer (at most 3 prior therapies for platinum resistant disease) | Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Patients With Recurrent Platinum-resistant Ovarian Cancer: Phase II Study | PA | View Drugs | View Results |
Evorpacept | CD47/SIRPa-blocking agent ALX148, CD47 antagonist ALX-148, ALX148 | Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis | Clinical Trials | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05465941 | II | Platinum resistant high grade serous ovarian cancer; at most one prior line of therapy for platinum resistant disease | Phase II Clinical Trial of PLX038 in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | MN | View Drugs | |
PLX038 | pegylated SN-38 conjugate PLX038 | Topoisomerase I inhibitor | Clinical Trials |
|
|
| NCT05479045 | II | Platinum resistant or refractory ovarian cancer | A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | DC, NJ | View Drugs | |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | NY-ESO-1 Peptide vaccine | | Immune response against cancer expressing NY-ESO-1 | Clinical Trials |
|
|
| NCT05489211 | II | Advanced solid tumors | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours | CA, IN, MA, MI, NJ, NM, NY, OH, TN, TX, WI | View Drugs | View Results |
AZD5305 | | PARP1 inhibitor | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Datopotamab deruxtecan | Anti-TROP2/DXd antibody-drug conjugate DS-1062a, Dato-DXd | ADC: anti-TROP2 + topoisomerase I inhibitor (Dxd) | Clinical Trials |
|
|
| NCT05512208 | II | Recurrent high grade serous, endometrioid or mucinous ovarian cancer with alterations in RAS, BRAF or NF1 | A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK) | OK | View Drugs | View Results |
Avutometinib | CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766 | RAF and MEK inhibitor | Clinical Trials | Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials |
|
|
| NCT05523440 | II | Recurrent ovarian cancer with ARID1A mutations | Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A) | OK | View Drugs | |
|
|
| NCT05538091 | II | Platinum resistant or refractory ovarian cancer | Phase II Clinical Trial Combining the Hedgehog Inhibitor Vismodegib With the PD-L1 Inhibitor Atezolizumab in Patients With Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | PA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Vismodegib | Hedgehog antagonist GDC-0449, Erivedge, GDC-0449 | Smoothened antagonist | Approved in Other Cancers |
|
|
| NCT05554328 | II | Recurrent or persistent ovarian cancer with alterations in BRAF, HRAS, KRAS, NRAS, MEK1/2 or NF1 | A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial | AL, AZ, CA, FL, ID, IL, IA, LA, ME, MD, MA, MI, MN, MO, MT, NV, NJ, NM, NY, ND, OH, OK, OR, PA, RI, SD, TX, WA, WV, WI | View Drugs | View Results |
Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | Selumetinib | ARRY-142886, AZD6244, Koselugo | MEK1/2 inhibitor | Approved in Other Cancers |
|
|
| NCT05554380 | II | Advanced solid tumors with an activating AKT mutation | Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial | AL, AZ, CA, FL, ID, IL, IA, ME, MD, MI, MN, MT, NV, NY, ND, OH, OK, OR, PA, SD, TX, WA, WI | View Drugs | View Results |
Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05554341 | II | Advanced solid tumors with prior taxane therapy | Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial | AL, AZ, CA, FL, ID, IL, IA, KY, LA, ME, MD, MI, MN, MO, MT, NV, NY, ND, OH, OK, OR, SD, TX, WA, WI | View Drugs | View Results |
|